Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Down – Time to Sell?

Autolus Therapeutics plc (NASDAQ:AUTL)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $2.18, but opened at $2.12. Autolus Therapeutics shares last traded at $2.14, with a volume of 615,672 shares traded.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on AUTL shares. Redburn Atlantic raised shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Friday, November 15th. Needham & Company LLC reissued a “buy” rating and set a $10.00 price objective on shares of Autolus Therapeutics in a research note on Thursday, December 5th. Finally, The Goldman Sachs Group upgraded shares of Autolus Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $7.00 to $7.60 in a research report on Monday, November 18th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Autolus Therapeutics presently has a consensus rating of “Buy” and an average target price of $10.40.

Autolus Therapeutics Stock Performance

The firm has a market capitalization of $580.08 million, a price-to-earnings ratio of -1.80 and a beta of 1.99. The business has a fifty day moving average price of $3.37 and a 200 day moving average price of $3.76.

Autolus Therapeutics (NASDAQ:AUTL) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same period in the prior year, the business posted ($0.26) earnings per share. On average, analysts expect that Autolus Therapeutics plc will post -0.94 earnings per share for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors have recently bought and sold shares of AUTL. ProShare Advisors LLC acquired a new position in shares of Autolus Therapeutics during the 2nd quarter valued at $43,000. Capstone Investment Advisors LLC acquired a new position in shares of Autolus Therapeutics during the third quarter worth about $51,000. Daiwa Securities Group Inc. lifted its stake in shares of Autolus Therapeutics by 2,659.7% during the second quarter. Daiwa Securities Group Inc. now owns 15,868 shares of the company’s stock worth $55,000 after purchasing an additional 15,293 shares in the last quarter. Herbst Group LLC purchased a new stake in shares of Autolus Therapeutics in the third quarter worth about $91,000. Finally, China Universal Asset Management Co. Ltd. grew its stake in shares of Autolus Therapeutics by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 38,393 shares of the company’s stock valued at $139,000 after buying an additional 14,959 shares in the last quarter. 72.83% of the stock is currently owned by hedge funds and other institutional investors.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.